000207621 001__ 207621
000207621 005__ 20230212173758.0
000207621 0247_ $$2CORDIS$$aG:(EU-Grant)765269$$d765269
000207621 0247_ $$2CORDIS$$aG:(EU-Call)H2020-MSCA-ITN-2017$$dH2020-MSCA-ITN-2017
000207621 0247_ $$2originalID$$acorda__h2020::765269
000207621 035__ $$aG:(EU-Grant)765269
000207621 150__ $$aImproving Genome Editing Efficiency (IMGENE)$$y2017-09-01 - 2021-08-31
000207621 371__ $$aINSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC$$dPortugal$$ehttp://www.ibmc.up.pt$$vCORDIS
000207621 371__ $$aMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)$$bMDC$$dGermany$$ehttp://www.mdc-berlin.de$$vCORDIS
000207621 371__ $$aIT University of Copenhagen$$bIT University of Copenhagen$$dDenmark$$ehttp://en.itu.dk/$$vCORDIS
000207621 371__ $$aACADEMISCH ZIEKENHUIS LEIDEN$$bLeiden University Medical Center$$dNetherlands$$ehttp://www.lumc.nl$$vCORDIS
000207621 371__ $$aASTRAZENECA AB$$dSweden$$ehttp://www.astrazeneca.com$$vCORDIS
000207621 371__ $$aUSTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE$$bUMG AV CR, v. v. i.$$dCzech Republic$$ehttp://www.img.cas.cz$$vCORDIS
000207621 371__ $$aUNIVERSITAETSKLINIKUM FREIBURG$$bUKLFR$$dGermany$$ehttp://www.uniklinik-freiburg.de/ip/splash/start.html$$vCORDIS
000207621 372__ $$aH2020-MSCA-ITN-2017$$s2017-09-01$$t2021-08-31
000207621 450__ $$aIMGENE$$wd$$y2017-09-01 - 2021-08-31
000207621 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000207621 680__ $$aCRISPR genome editing technology is considered to become the greatest technological improvement in biomedical research since the invention of the polymerase chain reaction 25 years ago and pharmaceutical companies as well as academic research are eager to apply it. However, the efficiency of introducing defined changes into the genome by CRISPR is still low, currently limiting its application in basic research, industry and gene therapy. IMGENE unites expert European research groups of academia and industry to address by innovative and complementary approaches the low efficiency of precise genome editing using CRISPR technology. To our best knowledge, IMGENE is the only concerted approach to tackle the important problem of low genome editing efficiency of CRISPR in a multidisciplinary, intersectorial manner. The IMGENE consortium consisting of 6 academic and 1 industrial beneficiary (AstraZeneca), 2 industrial partners (Taconic; MilliporeSigma), and the patient organization Genetic Alliance, aims to improve the genome editing efficiency of CRISPR by research training of 8 ESRs to unleash the full potential of this technology. Combining complementary knowledge on protein chemistry, molecular biology, cellular biology, viral vectors, transgenic mice, gene therapy, and bioinformatics present in the network, IMGENE will establish novel tools and protocols for improved CRISPR genome editing efficiency that will be of immediate benefit for health and life science research, the pharmaceutical industry, and the application of gene therapy. In addition, IMGENE addresses crucial ethical questions related to the application of genome editing technology in animals, plants, and humans, which have to be solved to gain acceptance by the society. By excellent research training of 8 ESRs on a scientifically and economically highly relevant topic and additional training in transferable skills, IMGENE will educate novel leaders with great career perspectives in industry and academia.
000207621 909CO $$ooai:juser.fz-juelich.de:839501$$pauthority$$pauthority:GRANT
000207621 909CO $$ooai:juser.fz-juelich.de:839501
000207621 970__ $$aoai:dnet:corda__h2020::b09a165093e32d1122714901d1899824
000207621 980__ $$aG
000207621 980__ $$aCORDIS
000207621 980__ $$aAUTHORITY